Bevacizumab治療復發性子宮頸癌的檢視

The Role of Bevacizumab in the Treatment of Women with Advanced or Recurrent Cervical Cancer

美國食品藥物管理局(FDA)在2014年通過，Bevacizumab（Avastin癌思停）一種抗血管增生藥物，抗血管內皮生長因子的單株抗體，可以阻斷血管生長、抑制內皮細胞的活性與增殖，腫瘤細胞會因沒有血管提供營養而使腫瘤逐漸萎縮而消失，可用於復發性子宮頸癌。臨床上，bevacizumab合併化學治療藥物已被證實，不影響生活品質且能增加患者存活率，但仍有副作用，如高血壓、尿蛋白、血栓栓塞、胃腸穿孔等。

Bevacizumab is an anti-VEGF (vascular endothelial growth factor) monoclonal antibody that blocks tumor angiogenesis by binding and inactivating VEGF and thereby inhibiting endothelial cells activation and proliferation, thus denying tumors the ability to recruit new vessel development. Recently, a combination of bevacizumab and chemotherapeutic agents demonstrates an overall survival benefit without a decrement in quality of life, compared to chemotherapy alone. However, treatment-related toxic effects observed with the incorporation of bevacizumab included mainly hypertension, proteinuria, thromboembolism and gastrointestinal perforation. The US FDA (Food and Drug Aministration) approved bevacizumab for recurrent cervical cancer in 2014 as the first anti-angiogenic therapy in gynecologic malignancies to demonstrate an overall survival benefit.